Cite
HARVARD Citation
Messersmith, W. et al. (n.d.). 389 Combining transcriptomic- and tissue-based immune biomarkers to evaluate GB1275, a CD11b modulator, as a single agent or with pembrolizumab in patients with advanced solid tumors. Journal for immunotherapy of cancer. pp. A236-A237. [Online].